Seite 1 von 5
neuester Beitrag: 26.05.20 16:09
eröffnet am: 13.01.09 13:17 von: _bbb_ Anzahl Beiträge: 124
neuester Beitrag: 26.05.20 16:09 von: bauwi Leser gesamt: 26522
davon Heute: 9
bewertet mit 4 Sternen

Seite: Zurück 1 | 2 | 3 | 4 | 5 | 5  Weiter  

13.01.09 13:17

5662 Postings, 4634 Tage _bbb_CCYC

Press Release Source: Cyclacel Pharmaceuticals, Inc.

Cyclacel Begins Phase 2 Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Tuesday January 13, 7:00 am ET

BERKELEY HEIGHTS, N.J., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NasdaqGM:CYCC - News) (NasdaqCM:CYCCP - News) announced today that the company has begun treating patients in a Phase 2, open label, single arm, multicenter clinical trial of sapacitabine (CYC682) in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy. This study builds on the observation of prolonged stable disease of four months or longer experienced by heavily pretreated NSCLC patients involved in two Phase 1 studies of sapacitabine. The multicenter Phase 2 trial is led by Philip D. Bonomi, M.D., the Alice Pirie Wirtz Professor of Medical Oncology at the Rush University Medical Center, Chicago.

``Nucleoside analogs, such as gemcitabine, have significant activity in NSCLC,'' said Dr. Bonomi. ``We are interested in evaluating sapacitabine because of its unique mechanisms of action, indication of activity in Phase 1 studies and the possibility that it may be an active drug in NSCLC that can be administered by the oral route.''

The primary objective of the study is to evaluate the rate of response and stable disease in patients with previously treated NSCLC. Secondary objectives are to assess progression-free survival, duration of response, duration of stable disease, one year survival, overall survival and safety. The study will enroll approximately 60 patients and has a lead-in phase for dose escalation with the objective of defining a recommended dose followed by a second stage in which patients will be treated at the recommended dose. Study completion is planned to occur approximately six months after the last patient is enrolled.

``The opening of this study marks the expansion of the Phase 2 program of sapacitabine into solid tumors,'' said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. ``We believe that sapacitabine has the potential to emerge as a novel, orally administered treatment for patients with both hematologic malignancies and solid tumors. During this quarter Cyclacel will meet with the U.S. FDA to discuss registration pathways for sapacitabine as a treatment for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) in elderly patients.''

About Sapacitabine

Cyclacel is now evaluating sapacitabine, an orally available nucleoside analog, in three Phase 2 trials in both hematological and solid tumors. Sapacitabine acts through a dual mechanism, interfering with DNA synthesis by causing single-strand DNA breaks and inducing arrest of cell cycle progression mainly at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite, have demonstrated potent anti-tumor activity in preclinical studies. Sapacitabine has been given as a single agent to approximately 170 patients with both hematologic malignancies and solid tumors in four Phase 1 studies. In Phase 1 trials reported earlier sapacitabine was evaluated in 47 pretreated patients with advanced leukemias or MDS and 123 heavily pretreated patients with various solid tumors. In the hematological malignancy trial six patients achieved complete remission or complete remission without platelet count recovery and a further 15 had a significant decrease in bone marrow blasts including 7 with blast reduction to 5% or less. In the solid tumor studies, 20 patients experienced prolonged stable disease and remained on study for four months or longer, five with NSCLC, one with small cell lung cancer, four with colorectal, two with bladder, two with gastrointestinal stromal tumors, two with ovarian, one with breast, one with renal, one with parotid and one with an unknown primary tumor. Sapacitabine is also being studied in a currently ongoing Phase 2 trial in patients with advanced cutaneous T cell lymphoma.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Several additional programs are at an earlier stage. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(TM) Liquid and Numoisyn(TM) Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology, oncology and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Please visit for additional information. Note: The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc.; Numoisyn(TM) and Xclair(R) are trademarks of Sinclair Pharma plc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words ``may,'' ``will,'' ``would,'' ``could,'' ``should,'' ``believes,'' ``estimates,'' ``projects,'' ``potential,'' ``expects,'' ``plans,'' ``anticipates,'' ``intends,'' ``continues,'' ``forecast,'' ``designed,'' ``goal,'' or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under ``Risk Factors'' in the Annual Report on Form 10-K for the year ended December 31, 2007, as supplemented by the interim quarterly reports, filed with the SEC.

         Cyclacel Pharmaceuticals, Inc.
         Corey Sohmer
         (908) 517-7330

         WeissComm Partners
         Aline Schimmel
         (312) 646-6295

         College Hill, Life Sciences
         Sue Charles
         Justine Lamond
         +44 (20) 7866 7857

Source: Cyclacel Pharmaceuticals, Inc.  
Seite: Zurück 1 | 2 | 3 | 4 | 5 | 5  Weiter  
98 Postings ausgeblendet.

01.11.17 15:17

252 Postings, 1182 Tage AndrolytNicht zu fassen

was aus 10% Plus übrig geblieben ist..einfach nur schäbig..  

02.11.17 15:09

252 Postings, 1182 Tage AndrolytHab mich

heute getrennt von diesem Wert.. Allen trotzdem viel Erfolg..  

04.12.17 21:36

18187 Postings, 3709 Tage Balu4u$2.19 * 0.22 11.17%

05.12.17 22:13

252 Postings, 1182 Tage AndrolytHier wird

vor den Daten am Montag ordentlich manipuliert,absolut sinnloser Absturz Heute  

12.12.17 14:16

252 Postings, 1182 Tage AndrolytBleibt eine

elende Schrottaktie..  

05.09.18 19:50

18187 Postings, 3709 Tage Balu4uErste Ausbruchversuche und höchtes Volumen

20.12.18 12:24

5495 Postings, 1086 Tage VassagoCYCC 0,695$ (-6%)

  • MK 9 Mio. $

  • Cash 19 Mio. $

20.12.18 15:01

22 Postings, 3781 Tage Bayernland1???

Was stimmt da nicht ß Ist die Pipeline Schrott ?  

20.04.20 16:25

5495 Postings, 1086 Tage VassagoCYCC 17.38$ (+167%)

Cyclacel versucht vom Corona Hype zu profitieren

Und zum Handelsende dann das Offering?


20.04.20 17:01

344 Postings, 445 Tage BananiBei 860k outstanding Shares gibt es garantiert

ein Offering zumal die Anzahl durch einen 1:20 RS am 14 April 2020 reduziert wurde.  

21.04.20 16:29

5495 Postings, 1086 Tage VassagoCYCC 4.35$ (-49%)


  • 4 Mio. neue Aktien zu je 5$ ~20 Mio. $

So ein durchsichtiges Manöver, erst eine "Corona PR" rausbringen und danach sofort ein Offering.


13.05.20 15:03

7738 Postings, 7521 Tage bauwiPlötzliches Volumen und Interesse an der Aktie

Scheint sich was anzubahnen. Haben die etwas in Petto?
MfG bauwi
Die Freiheit des Menschen liegt nicht darin, daß er tun kann, was er will, sondern das er nicht tun muß, was er nicht will.

13.05.20 15:23

7738 Postings, 7521 Tage bauwiP Ä N G !! Explodiert dieser Biotechplayer?

In USA hat sich im vorbörslichen Bereich auch schon etwas getan.
Nachdem diese Aktie eine längere Seitwärtsphase nach einer kräftigen Korrektur hinter sich gebracht hatte, ist sie heute sogar bis auf 5 ? gesprungen!!
Wie geht's weiter?
MfG bauwi
Die Freiheit des Menschen liegt nicht darin, daß er tun kann, was er will, sondern das er nicht tun muß, was er nicht will.
Angehängte Grafik:
cycc.jpg (verkleinert auf 60%) vergrößern

13.05.20 16:40

7411 Postings, 2771 Tage iTechDachsLeider erstmal gar nicht - die nächsten Daten

gibt es voraussichtlich Ende des Jahres - wenn alles gut geht und die Partner mitspielen: soll heissen die Daten des Dana Farber Cancer Institute bis dahin trotz CoVID19 erhoben und ausgewertet werden können sowie die angedachten Konferenzen - zumindest virtuell stattfinden - werden.


13.05.20 17:47

7738 Postings, 7521 Tage bauwi@ iTechDachs Danke!

Was war dann das heute?
MfG bauwi
Die Freiheit des Menschen liegt nicht darin, daß er tun kann, was er will, sondern das er nicht tun muß, was er nicht will.

20.05.20 15:20

7738 Postings, 7521 Tage bauwi#110 von den 8 $ sind wir weit entfernt! Hab

nochmal gekauft!    Der Kurs wird sowieso in NY gemacht.
Das Unternehmen hat schließlich zusätzlich Alterserkrankungen auf der Agenda. Um Covid19 geht's mir gar nicht. Hauptsache bin hier schon mal positioniert!
Bei Cytodyne ist auch warten angesagt, weshalb die Techs das Ganze überbrücken.  
MfG bauwi
Die Freiheit des Menschen liegt nicht darin, daß er tun kann, was er will, sondern das er nicht tun muß, was er nicht will.

21.05.20 23:07

7738 Postings, 7521 Tage bauwiCyclacel wird wieder entdeckt! In USA steigen

steigen die Umsätze und auch der Kurs!   Spannend, wenn die Aktie den Spielraum nach oben nutzt!
Es ist die Zeit der Bio-Pharma-Firmen!
MfG bauwi
Die Freiheit des Menschen liegt nicht darin, daß er tun kann, was er will, sondern das er nicht tun muß, was er nicht will.

22.05.20 13:06

7738 Postings, 7521 Tage bauwiAktie schraubt sich zuverlässig jeden Tag ins Plus

Einfach mal auf den Chart blicken. Dann wird klar, wieviel Luft nach oben besteht.
Insider wissen schon mehr!
MfG bauwi
Die Freiheit des Menschen liegt nicht darin, daß er tun kann, was er will, sondern das er nicht tun muß, was er nicht will.

25.05.20 11:13

7738 Postings, 7521 Tage bauwiMorgen geht's wieder richtig hoch! Kurse werden

in USA gemacht!  
MfG bauwi
Die Freiheit des Menschen liegt nicht darin, daß er tun kann, was er will, sondern das er nicht tun muß, was er nicht will.

26.05.20 16:09

7738 Postings, 7521 Tage bauwiUnd weiter geht's nach Norden!

Während andere schwächeln  :-)
MfG bauwi
Die Freiheit des Menschen liegt nicht darin, daß er tun kann, was er will, sondern das er nicht tun muß, was er nicht will.

Seite: Zurück 1 | 2 | 3 | 4 | 5 | 5  Weiter  
   Antwort einfügen - nach oben